Todd Anderman Sells 11,132 Shares of Ocular Therapeutix (NASDAQ:OCUL) Stock

Key Points

• Insider Todd Anderman sold 11,132 shares of Ocular Therapeutix (NASDAQ:OCUL) at an average price of $12.34, totaling approximately $137,368.88, reducing his position by 11.28%.
• Ocular Therapeutix reported a quarterly earnings loss of ($0.39) per share, missing estimates, while revenue was $13.46 million, exceeding expectations but down 17.7% year-over-year.
• Multiple analysts have set price targets for OCUL stock with a consensus average target of $22.63, and a majority rating of "buy," indicating a positive outlook for the company's stock performance.

Ocular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) insider Todd Anderman sold 11,132 shares of the stock in a transaction that occurred on Wednesday, October 8th. The shares were sold at an average price of $12.34, for a total value of $137,368.88. Following the transaction, the insider directly owned 87,568 shares of the company's stock, valued at $1,080,589.12. The trade was a 11.28% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Ocular Therapeutix Price Performance

Shares of OCUL stock traded down $0.16 during trading hours on Friday, reaching $11.78. The company had a trading volume of 3,112,213 shares, compared to its average volume of 2,031,290. The company has a debt-to-equity ratio of 0.23, a quick ratio of 10.02 and a current ratio of 10.10. The stock has a fifty day moving average of $12.28 and a 200-day moving average of $9.83. The company has a market capitalization of $2.05 billion, a price-to-earnings ratio of -9.20 and a beta of 1.45. Ocular Therapeutix, Inc. has a 12-month low of $5.78 and a 12-month high of $13.85.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.04). The business had revenue of $13.46 million during the quarter, compared to analysts' expectations of $13.12 million. Ocular Therapeutix had a negative return on equity of 71.92% and a negative net margin of 382.51%.The company's revenue was down 17.7% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.26) earnings per share. On average, equities analysts anticipate that Ocular Therapeutix, Inc. will post -0.98 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have commented on OCUL. Piper Sandler upped their price target on Ocular Therapeutix from $21.00 to $31.00 and gave the stock an "overweight" rating in a research note on Friday, October 3rd. Chardan Capital restated a "buy" rating and set a $21.00 price target on shares of Ocular Therapeutix in a research note on Thursday, October 2nd. Scotiabank reduced their price objective on Ocular Therapeutix from $22.00 to $20.00 and set a "sector outperform" rating on the stock in a research note on Wednesday, August 6th. Needham & Company LLC increased their price objective on Ocular Therapeutix from $15.00 to $20.00 and gave the company a "buy" rating in a research note on Wednesday, October 1st. Finally, HC Wainwright increased their price objective on Ocular Therapeutix from $15.00 to $19.00 and gave the company a "buy" rating in a research note on Wednesday. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Ocular Therapeutix presently has an average rating of "Moderate Buy" and an average target price of $22.63.

Institutional Investors Weigh In On Ocular Therapeutix

Several institutional investors have recently modified their holdings of the company. Nisa Investment Advisors LLC raised its position in shares of Ocular Therapeutix by 62.9% during the 2nd quarter. Nisa Investment Advisors LLC now owns 3,604 shares of the biopharmaceutical company's stock worth $33,000 after purchasing an additional 1,392 shares during the last quarter. Brooklyn Investment Group increased its holdings in Ocular Therapeutix by 151.5% in the 1st quarter. Brooklyn Investment Group now owns 5,238 shares of the biopharmaceutical company's stock valued at $38,000 after purchasing an additional 3,155 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in Ocular Therapeutix by 17.0% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,154 shares of the biopharmaceutical company's stock valued at $57,000 after purchasing an additional 893 shares in the last quarter. GAMMA Investing LLC boosted its position in Ocular Therapeutix by 6,760.0% in the 1st quarter. GAMMA Investing LLC now owns 8,232 shares of the biopharmaceutical company's stock valued at $60,000 after buying an additional 8,112 shares during the last quarter. Finally, Trust Co. of Vermont raised its stake in shares of Ocular Therapeutix by 16.1% in the 2nd quarter. Trust Co. of Vermont now owns 7,200 shares of the biopharmaceutical company's stock valued at $67,000 after purchasing an additional 1,000 shares in the last quarter. Hedge funds and other institutional investors own 59.21% of the company's stock.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.